News | July 27, 2025
Dr. Reddy’s infuses Rs. 565 crore in its Russian subsidiary
The company has made an investment of Rs. 565.40 crore in DRL Russia for a total equity stake of 45.19%
The company has made an investment of Rs. 565.40 crore in DRL Russia for a total equity stake of 45.19%
Laurus Labs has reported total income of Rs. 1,580 crores during the period ended June 30, 2025
Solara Active Pharma Sciences has reported total income of Rs. 320.13 crores during the period ended June 30, 2025
_256_384.jpg)
Cipla has reported total income of Rs. 7,216.03 crores during the period ended June 30, 2025
RPG Life Sciences has reported total income of Rs. 174.15 crores during the period ended June 30, 2025
This GMP certification for our sterile drug product manufacturing facility, Goa Plant II is a testament to our relentless efforts to supply quality and affordable medicines across geographies
The scheme aims to avoid disruption in supply of critical active pharmaceutical ingredients (APIs) used to make critical drugs
The company received one observation in the Form-483
Both these products will be manufactured at Lupin’s Injectable facility at Nagpur, India
Ibrutinib tablets will be produced at Zydus Lifesciences Ltd (SEZ), Ahmedabad
Subscribe To Our Newsletter & Stay Updated
